for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlycoMimetics Inc

GLYC.OQ

Latest Trade

5.91USD

Change

0.34(+6.10%)

Volume

41,073

Today's Range

5.60

 - 

5.97

52 Week Range

2.65

 - 

13.56

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.57
Open
5.60
Volume
41,073
3M AVG Volume
5.89
Today's High
5.97
Today's Low
5.60
52 Week High
13.56
52 Week Low
2.65
Shares Out (MIL)
43.36
Market Cap (MIL)
249.75
Forward P/E
-4.36
Dividend (Yield %)
--

Latest Developments

More

Glycomimetics - Cash And Cash Equivalents Of $170.9 Mln As Of Sept 30

GlycoMimetics Reports Second Quarter 2019 Financial Results And Recent Operational Highlights

Glycomimetics Files For Mixed Shelf Of Up To $250 Million – SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlycoMimetics Inc

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

Industry

Biotechnology & Drugs

Contact Info

9708 Medical Center Dr

+1.240.2431201

http://www.glycomimetics.com/

Executive Leadership

Timothy R. Pearson

Independent Chairman of the Board

Rachel K. King

President, Chief Executive Officer, Co-Founder, Director

John Magnani

Co-Founder, Senior Vice President, Chief Scientific Officer

Brian Hahn

Chief Financial Officer

Armand Girard

Senior Vice President, Strategy and Corporate Development

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.500

2017

-1.130

2018

-1.180

2019(E)

-1.346
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.49
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-29.36
Return on Equity (TTM)
-28.14

Latest News

Latest News

BRIEF-Glycomimetics Reports Qtrly Loss Per Share Of $0.33

* GLYCOMIMETICS INC - AS OF MARCH 31, 2018, GLYCOMIMETICS HAD CASH AND CASH EQUIVALENTS OF $242.6 MILLION AS COMPARED TO $123.9 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

BRIEF-GlycoMimetics Announces Proposed Public Offering Of Common Stock

* GLYCOMIMETICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Glycomimetics Reports Q4 Loss Per Share $0.27

* GLYCOMIMETICS REPORTS FOURTH QUARTER AND YEAR-END 2017 RESULTS

BRIEF-Glycomimetics Enters Agreement With Hovon To Initiate Study Startup Activities For Planned Clinical Trial Of GMI-1271 And Decitabine

* GLYCOMIMETICS ENTERS INTO AGREEMENT WITH HOVON TO INITIATE STUDY STARTUP ACTIVITIES FOR PLANNED CLINICAL TRIAL OF GMI-1271 AND DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE UNFIT FOR CHEMOTHERAPY

BRIEF-GlycoMimetics qtrly loss per share $‍0.24

* Glycomimetics reports program updates and third quarter 2017 results

BRIEF-GlycoMimetics says files for mixed shelf of upto $250 mln

* GlycoMimetics Inc says files for mixed shelf of upto $250.0 million - SEC filing Source text: (http://bit.ly/2xOoKE6) Further company coverage:

BRIEF-GlycoMimetics Inc says to receive European patent for GMI-1271

* GlycomiMetics Inc says to receive European patent for GMI-1271; will have claims directed at GMI-1271 extending at least until 2032 Source text for Eikon: Further company coverage:

BRIEF-Glycomimetics' GMI-1271 receives EU orphan drug designation

* Glycomimetics' GMI-1271 receives EU orphan drug designation for acute myeloid leukemia Source text for Eikon: Further company coverage:

BRIEF-Glycomimetics announces pricing of public offering of common stock

* Glycomimetics announces pricing of public offering of common stock

BRIEF-Glycomimetics Inc terminates sales agreement with Cowen and Company

* Glycomimetics Inc - co terminated its sales agreement, dated March 1, 2016, with Cowen and Company Source text for Eikon: (http://bit.ly/2qaOyrv) Further company coverage:

BRIEF-Glycomimetics announces proposed public offering of common stock

* Glycomimetics announces proposed public offering of common stock

BRIEF-Glycomimetics reports supportive biomarker data from early-stage trial of GMI-1271

* GlycoMimetics announces high overall response rates, low induction mortality, promising initial survival outcomes, and supportive biomarker data from phase 1/2 trial of GMI-1271 in AML Source text for Eikon: Further company coverage:

BRIEF-Glycomimetics reports qtrly net loss per share of $0.34

* Glycomimetics reports program updates and first quarter 2017 results

BRIEF-Glycomimetics Q4 loss per share $0.36

* Glycomimetics reports fourth quarter and year-end 2016 results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up